Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.76, $0.06 better than the analyst estimate of $0.70. Revenue for the quarter came in at $759.3 million versus the consensus estimate of $724.26 million.

"We are very pleased to report strong second quarter performance, which reflected significant growth in the number of patients and physicians choosing transcatheter heart valve therapy," said Michael A. Mussallem, chairman and CEO. "Our results this quarter were better than expected, driving strong top and bottom line growth."

GUIDANCE:

Edwards Lifesciences sees FY2016 EPS of $2.78-$2.88, versus the consensus of $2.76.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.